TMCnet News
Research and Markets: Dementia - Pipeline Review, H2 2012: Plan Mergers and Acquisitions Effectively By Identifying Players of the Most Promising PipelineDUBLIN --(Business Wire)-- Research and Markets (http://www.researchandmarkets.com/research/wrvp9r/dementia) has announced the addition of Global Markets Direct's new report "Dementia - Pipeline Review, H2 2012" to their offering. Global Markets Direct's, 'Dementia - Pipeline Review, H2 2012', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Dementia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Dementia. Dementia - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC (News - Alert) filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Scope - A snapshot of the globl therapeutic scenario for Dementia. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Dementia pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Dementia. - Devise corrective measures for pipeline projects by understanding Dementia pipeline depth and focus of Indication therapeutics. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Companies Mentioned: Abbott Laboratories GlaxoSmithKline plc Sylentis Astellas Pharma Inc. Eisai Co., Ltd. Kowa Company, Ltd. Merz GmbH & Co. KGaA Neuren Pharmaceuticals Limited ProteoTech, Inc. The University of Tokyo WhanIn Pharmaceutical Co., Ltd. SYGNIS Pharma AG Allon Therapeutics Inc. MediPost Co., Ltd. e-Therapeutics plc Oryzon TauRx Therapeutics Ltd Acumen Pharmaceuticals, Inc. BIOALVO S.A. IMMD Inc. Neurimmune Therapeutics AG BioArctic Neuroscience AB Intellect (News - Alert) Neurosciences, Inc. Sparsha Pharma International Pvt. Ltd. Tautatis Incorporated Stelic Institute & Co. Varinel, Inc. For more information visit http://www.researchandmarkets.com/research/wrvp9r/dementia Source (News - Alert): Global Markets Direct
|